Project
Novartis_CAIN457C22301
Ongoing - recruitment active ยท 2023 until 2026
Rubbert-Roth Andrea, Schmiedeberg Kristin, Bartz-Batliner Mira, Peischl Shirin, Gostic Dragana
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Ongoing - recruitment active
Start Date
2023
End Date
2026
Financing
Others
Phase
III
Brief description/objective
A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase3 trial to evaluate efficacy and safety of secukinumab administered subcutaneously versus placebo,in combination with a glucocorticoid taper regimen, in patients with polymyalgia rheumatica (PMR)